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Abstract
Importance: In vivo confocal microscopy (IVCM) provides high-resolution
images of the ocular surface and has been validated in trachomatous conjuncti-
val scarring.
Background: This study used IVCM to identify parameters associated with
clinical scarring progression.
Design: Prospective cohort study.
Participants: A total of 800 participants in Northern Tanzania with
trachomatous scarring.
Methods: Participants underwent clinical examination, photography and
IVCM at baseline and 24-months. Clinical progression of scarring was defined
by comparing baseline and 24-month photographs. Masked grading of IVCM
images was used to identify scarring at both time points. Multivariable logistic
regression was used to assess factors associated with clinical progression.
Main Outcome Measures: Risk factors associated with clinical scarring
progression.
Results: Clinical and IVCM assessment of 800 participants were performed at
baseline, with 617 (77.1%) seen at 24-months. Of these, 438 of 617 (71.0%) had
gradable IVCM images at both time points and 342 of 438 (78.1%) of these
could be graded as showing definite clinical progression or no progression on
image comparison. Clinical progression was found to occur in 79 of
342 (23.1%). After adjusting for age and sex, clinical scarring progression was
strongly associated with a high IVCM connective tissue organization score at
both baseline (odds ratio [OR] = 1.84 for each increase in scarring category;
P = .002) and 24-months (OR = 1.60; P = .02). Dendritiform cells present at
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24-months were strongly associated with clinical scarring progression after
adjustment (OR = 2.62; P = .03).
Conclusions and Relevance: Quantitative IVCM parameters, including con-
nective tissue organization score and the presence of dendritiform cells, are
associated with disease progression and may be useful markers in trachoma
and other conjunctival fibrotic diseases.
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1 | INTRODUCTION
Trachoma is the most common cause of infectious blind-
ness worldwide. It is caused by infection of the conjuncti-
val epithelium with Chlamydia trachomatis which
initiates an inflammatory reaction producing a mixed pap-
illary and follicular conjunctivitis. This active trachoma is
normally found in children who are subsequently at risk
of developing conjunctival scarring, entropion, trichiasis,
corneal opacity and blindness in later life. There are esti-
mated to be 157 million people globally who live in
regions requiring trachoma control interventions, with 1.5
million requiring treatment for trichiasis. In 2017 there
were 231 447 who were managed for trachomatous trichi-
asis.1 Around 2.2 million people are visually impaired
from trachoma, of whom 1.2 million are blind, the vast
majority in low- and middle-income countries.2,3 The
pathogenesis of trachomatous scarring, however, is poorly
understood.3,4 Chlamydial infection is rarely found in the
cicatricial stages and the factors driving the scarring pro-
cess need to be elucidated.5
In vivo confocal microscopy (IVCM) provides non-
invasive, high resolution images of living tissue down to
the cellular level. It is based on the optical principle of
confocality of the illumination and observation systems,
where both are focused on the same focal points.6 Any
light that is outside of this focal plane is therefore highly
suppressed, significantly increasing the resolution. In
contrast, the maximum resolution of a light-based bio-
microscope system, such as the slit lamp, is considerably
limited in comparison due to the amount of scattered
light. Due to the high resolution and magnification, the
confocal field of view is very small. The confocal micro-
scope therefore rapidly scans the focal point through the
tissue and reconstructs an image. This image is parallel
to the surface being examined.
IVCM has been used within ophthalmology to study a
wide range of ocular surface diseases, specifically in the
aid to diagnosing and monitoring microbial keratitis
including the detection of fungal hyphae and
acanthamoeba cysts, performing endothelial cell counts,
and assessing potentially malignant lesions.6-12 It is non-
invasive, safe and can be repeated.13,14 IVCM allows the
user to assess the inflammatory cell infiltrate, cellular
types and degree of connective tissue scarring. However,
interpreting the results can be challenging and there is a
lack of standardized, validated grading systems. Inter-
preting IVCM scans without masking clinical informa-
tion or other data, as is the case in many studies,15,1617
opens the potential for bias and raises questions over
interpretation.
We have previously reported a grading system for the
quantitative assessment of IVCM images in scarring tra-
choma.18-20 This grading system had good inter-observer
agreement (intra-class coefficient of 0.88), showed that
IVCM can be used to quantify connective tissue scarring
and measure the degree of inflammatory cell infil-
trate.18-20 We also found that the presence of
trachomatous scarring was strongly associated with the
presence of dendritiform cells (DFCs).19 This present
study looked at the use of this grading system in a cohort
of individuals with trachomatous scarring to identify if
the IVCM presence of DFC and/or scarring are associated
with clinical scarring progression.
2 | METHODS
2.1 | Ethical permission and subject
recruitment
This study was approved jointly by the London School of
Hygiene and Tropical Medicine Ethics Committee (Ref.
5128), the Kilimanjaro Christian Medical Centre Ethics
Committee (Ref. 203), and the National Ethics Commit-
tee of the Tanzanian National Institute of Medical
Research (Ref. NIMR/HQ/R.8a/Vol. IX/739). Informed
consent was obtained before enrolment of each subject.
This work adhered to the tenets of the Declaration of
Helsinki.
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This study was part of a series of studies on the patho-
genesis of trachomatous scarring.3,18,20-22 These involved
the recruitment of 800 adults with trachomatous con-
junctival scarring in trachoma endemic communities in
Siha District, Kilimanjaro Region, Northern Tanzania.
Children and those with trichiasis were excluded. We
attempted IVCM examinations on all consenting individ-
uals. Subjects were then re-examined after 24 months fol-
lowing baseline assessment.
2.2 | Clinical and photographic
assessment
Subjects were examined at baseline in a dark room or
tent with ×2.5 loupes and a bright torch. Signs of tra-
choma were graded using the 1981 detailed World
Health Organization (WHO) grading system, which
assesses the upper palpebral conjunctiva for follicles,
papillae, and scarring, and grades entropion/trichiasis
and corneal opacity.23 A modified grading system for
assessment of conjunctival scarring was used (Table 1
and Figure 1).19,22 A portable slit lamp was used if a
more magnified view was needed.
High-resolution digital photographs were taken of
the upper tarsal conjunctiva under standardized condi-
tions by the same photographer. Subjects were re-
examined and photographed after 24 months. Two
ophthalmologists independently identified clinical scar-
ring progression by comparing the high-resolution digital
photographs at 24 months to those taken at baseline. To
do this, the baseline and 24-month tarsal conjunctival
photographs were directly compared side-by-side.
Individuals with progressive scarring, “Progressors,” were
defined as those with clear photographic evidence of
increased conjunctival scarring at 24-months. “Non-pro-
gressors” clearly did not have photographic evidence of
scarring progression. Any disparities in progression status
were discussed and agreement reached.
2.3 | IVCM assessment
IVCM examination of the upper tarsal conjunctiva was
performed at baseline and again at 24 months using the
Heidelberg Retina Tomograph 3 (HRT) in combination
with the Rostock Corneal Module (RCM), Heidelberg
Engineering GmbH, Dossenheim, Germany using a pre-
viously described protocol.20 In brief, IVCM was per-
formed to the upper tarsal conjunctiva in the left eye of
subjects. Topical anaesthesia was applied to the conjunc-
tival sac (proxymetacaine 0.5%, Chauvin Pharmaceuticals
Ltd., Surrey, UK), and the upper eyelid was everted.
Scans were taken using the “volume” setting in which
40 coronal images are taken in rapid succession at 2.1-μm
intervals from superficial to deep. Scans started at the
conjunctival epithelial surface, and the final scan was at
a depth of 85 μm. Ten volume scans were taken from dif-
ferent locations from the whole of the tarsal conjunctival
surface. It was not possible to record the locations of
these scans due to the size of the area being scanned. All
IVCM examinations were conducted by the same experi-
enced operator (VH).
The IVCM images were graded for the presence of
DFCs and the degree of subepithelial connective tissue
organization and scarring, using the previously reported
grading system.19,20 Although other characteristics can be
seen on IVCM such as tissue oedema, papillae and
inflammatory infiltrate, these were not graded in this cur-
rent study. IVCM grading was performed by one of two
ophthalmologists (VH or JH) who were masked to the
clinical status of the patient. Both graders have significant
clinical experience in performing and interpreting corneal
and tarsal conjunctival IVCM from large scale clinical
studies in Tanzania and Nepal. For every subject, each
volume scan was assessed and scored: 0 (normal), 1 (grade
1), 2 (grade 2) or 3 (grade 3) for the connective tissue scar-
ring. The overall IVCM connective tissue organization
score for that subject was calculated by dividing the sum
of these separate volume scan scores by the number of
volume scans graded. Individuals with fewer than three
gradable volume scans were excluded from the analysis.
To grade the presence or absence of DFCs, all of the avail-
able IVCM images were used. Within each volume scan,
the section scan with the greatest number of DFCs was
used and counted. The mean number of DFCs per volume
TABLE 1 Clinical Scarring Grading System for the tarsal
conjunctiva
Grade Definition
S1 Scarring occupying <1/3 of the upper lida
S1a One or more pinpoint scars and/or a single
line of scarring less than 2 mm in lengthb
S1b Multiples lines of scarring less than 2 mm in length
S1c One or more lines/patches of scarring each 2 mm
or more in length/maximal dimension
S2 Patches of scarring occupying in surface
area ≥ 1/3 but <2/3 of the upper lid
S3 Patches of scarring occupying in surface area ≥ 2/3
of the upper lid
a“Upper lid” refers to zones 2 and 3 of the everted lid.23
bTwo millimetre was chosen as this is the approximate width of the
lower lid margin, which is readily available for comparison.
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scan was then calculated. If the mean was equal to, or
greater than 1, DFCs were counted as being present.19,20
2.4 | Data analysis
Data were entered into Access 2016 (Microsoft Corp,
Redmond, Washington) and analysed using STATA 14.0
(StataCorp LP, College Station, Texas). Multivariable
logistic regression models were fitted to assess whether
scarring progression was independently associated with
the degree of IVCM scarring at baseline or follow-up
and the presence or absence of DFCs after adjusting for
age. Likelihood ratio tests were used to assess the
strength of association of factors with scarring and tests
for non-linearity were conducted to assess whether
fitting IVCM connective tissue organization score and
age increases on a linear scale provided an adequate fit
to the data. The t-test was used to compare the differ-
ence in connective tissue organization score from
24 months and baseline between progressors and non-
progressors.
3 | RESULTS
3.1 | Study participants
We recruited 800 participants with pre-existing tarsal
conjunctival scarring at baseline and re-examined
617 (77.1%) of these at 24 months. Gradable IVCM
images, for both baseline and 24-months, were available
for 438 of 617 (71.0%) participants. Of these 438, consen-
sus could be reached between the two ophthalmologists
performing the photographic grading comparisons,
enabling us to confidently determine scarring progression
or non-progression in 342 (78.1%), of whom 79 (23.1%)
had clinical progression. For validity of the photographic
grades, masked grading of a selection of 50 random pho-
tographs was performed, giving an intra-class (kappa) co-
efficient of 0.68. These 342 participants were included in
the analysis. There was no difference in baseline charac-
teristics between the 800 participants initially recruited
and the 342 included in the analysis. Baseline demo-
graphic and clinical scarring data of the 342, by progres-
sion status, are shown in Table 2.
We have previously reported good inter-observer
agreement for the connective tissue scarring grading
(intra-class coefficient of 0.88).19,20 Inter-observer agree-
ment was re-assessed for the graders in this current study
using a random sample of 50 patients, who were again
masked to the clinical appearance. The intra-class corre-
lation co-efficient showed a good agreement of 0.72, that
is, 72% of the total variance was due to between individ-
ual variation (rather than between observer variation).
The percent agreement between the two observers
was 95.3%.
3.2 | IVCM parameters and clinical
scarring progression
There was strong evidence of an association between
clinical scarring progression at 24-months and an
increase in IVCM connective tissue organization score at
baseline, after adjusting for age (odds ratio [OR] = 1.81
for each increase in connective tissue organization score;
P = .002), Table 3. To add face validity, we performed an
analysis at 24-months. This, similar to the baseline analy-
sis, demonstrated that an increase in IVCM connective
tissue organization score at the 24-month review was
associated with clinical scarring progression at
FIGURE 1 Clinical grading system for trachomatous conjunctival scarring. A, Normal. B, Grade S1a. C, Grade S1b. D, Grade S1c. E,
Grade S2. F, Grade S3. Source: From Hu et al,19 with permission
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24-months, adjusting for age (adjusted OR = 1.60 for
each increase in connective tissue organization score;
P = .02), Table 3.
There was little evidence that progressive scarring
was associated with the detection of DFCs at baseline
(Table 3). For face validity purposes, we also looked for
an association between DFCs at the 24 month review and
clinical scarring progression at 24 months. This con-
firmed there was evidence that progressive scarring by
24-months was associated with the IVCM detection of
DFCs present at the 24-month timepoint (adjusted
OR = 2.53; P = .03), Table 3.
3.3 | Baseline and 24-month IVCM
connective tissue organization scores
There was no evidence of an association between the
baseline and 24-month IVCM connective tissue organiza-
tion scores. Figure 2 is a histogram showing the
difference in the IVCM connective tissue score between
24 months and baseline, showing a normal distribution
around 0. The mean difference in this IVCM connective
tissue organization score was almost identical for those
that showed clinical progression (−0.19) and those that
did not (−0.08; P = .23).
4 | DISCUSSION
In this cohort study of individuals with trachomatous
scarring examined over 2 years, connective tissue organi-
zation score and the presence of DFCs were associated
with disease progression.
Increasing IVCM connective tissue organization score
at both baseline and at the 24-month follow-up were asso-
ciated with clinical scarring progression. This suggests
that a high IVCM connective tissue organization score at
baseline could potentially be used to help identify individ-
uals at increased risk of clinical scarring disease
TABLE 2 Baseline demographic and clinical scarring data by progression status
Parameter
Clinically did not progress Clinically progressed
P-valuen (%)a n (%)a
Sex (N) 263 79 .36
Female 159 (75) 53 (25)
Male 104 (80) 26 (20)
Age group (N) 263 79 <.001
18 to 25 38 (88.4) 5 (11.6)
26 to 35 64 (88.9) 8 (11.1)
36 to 45 66 (82.5) 14 (17.5)
46 to 55 39 (72.2) 15 (27.8)
56 to 65 28 (63.6) 16 (36.4)
>65 28 (57.1) 21 (42.9)
Mean age in years (95% CI) 42.1 (40.1-44.1) 52.0 (48.4-55.8) <.001
Ethnicity (N) 260 79 .24
Maasai 186 (76.9) 56 (23.1)
Chagga 41 (83.7) 8 (16.3)
Meru 14 (77.8) 4 (22.2)
Other 19 (63.3) 11 (36.7)
Baseline conjunctival scarring grade (N) 258 75 <.001
S1a 78 (89.7) 9 (10.3)
S1b 108 (83.1) 22 (16.9)
S1c 53 (66.3) 27 (33.8)
2 9 (47.4) 10 (52.6)
3 10 (58.8) 7 (41.2)
Abbreviation: CI, confidence interval.
aRow percentages.
HOFFMAN ET AL. 5
progression. This finding also supports the suggestion that
the connective tissue morphology on IVCM may represent
subclinical scarring changes in the structure of the tarsal
conjunctiva.19,20 We have previously reported a strong
association between IVCM connective tissue organization
score and the histopathological scarring grade.18
However, the IVCM connective tissue organization
score for individual participants could either increase,
remain stable, or decrease, irrespective of whether there
had been clinical progression or not. We expected an
increase in scarring in IVCM parameters between base-
line and 24-months, but Figure 2 demonstrates a normal
distribution of difference in scarring between the two
time points. There are a number of reasons why this may
be the case. Firstly, the area visualized with the confocal
microscope is very small (400 by 400 μm) and it is not
possible to scan the same area twice nor map the area.
We tried to address this by taking 10 random scans over
the tarsal conjunctiva at each time point but we speculate
that areas of scarred conjunctiva identified at the initial
scan may then have been missed at the 24-month scan. It
would be interesting to repeat the scans over a longer
time period when the progression in clinical scarring is
more pronounced. Secondly, although we had good inter-
observer agreement some variability in the IVCM grading
may also have contributed to the apparent lack of IVCM










n (%)a n (%)a OR 95% CI P-value OR 95% CI P-value
Connective tissue organization
score at baseline
N = 257b N = 77b 2.15c 1.51 to 3.07 <.001 1.81c 1.24 to 2.64 .002
<1 118 (84.9) 21 (15.1)
1 to 2 107 (78.7) 29 (21.3)
>2 to 3 32 (54.2) 27 (45.8)
Connective tissue organization
score at 24 months
N = 259b N = 76b 1.84c 1.27 to 2.33 .01 1.57c 1.07 to 2.33 .02
<1 137 (82.5) 29 (17.5)
1 to 2 103 (76.9) 31 (23.1)
>2 to 3 19 (54.3) 16 (45.7)
Dendritiform cells at baseline N = 263b N = 79b 1.91 1.00 to 3.66 .05 1.52 0.77 to 3.02 .23
Present 33 (66.0) 17 (34.0)
Absent 230 (78.8) 62 (21.2)
Dendritiform cells present
at 24 months
N = 263b N = 79b 3.04 1.39 to 6.64 .005 2.53 1.11 to 5.77 .03
Present 16 (55.2) 13 (44.8)
Absent 247 (78.9) 66 (21.1)
Abbreviation: CI, confidence interval; OR, odds ratio.
aRow percentages;
bThe denominator (N) is less for the connective tissue organization score parameter than the dendritiform cells parameter as the protocol
required at least three gradable scans for connective tissue grading to be available.
cThe OR is the increase with each increase in connective tissue organization score category.
FIGURE 2 Density histogram showing the difference in the
mean in vivo confocal microscopy connective tissue organization
score between baseline and 24-month follow-up for non-
progressors and progressors
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scarring progression. Thirdly, when papillary inflamma-
tion was present (as was often the case in scarred partici-
pants) the epithelium became thickened and it was
difficult to visualize the deeper connective tissue. We
kept the HRT-RCM confocal microscope on an automatic
gain setting, facilitating subjective interpretation of
images rather than quantitative analysis. While this
approach worked well overall, dense clinical scarring
sometimes gave a rather amorphous appearance on the
IVCM image, rather than the typical organized appear-
ance, with little to differentiate the tissue morphology.
This may have led to under-grading on our connective
tissue organization score and is a potential limitation of
assessing the connective tissue with IVCM. However, the
results may also reflect the fact that connective tissue
analysis with the IVCM according to our protocol may
not be showing what we think it is showing and that fur-
ther research is needed to understand exactly what IVCM
is measuring.
We were able to accurately grade 71% of IVCM scans.
One of the main reasons for not being able to capture
gradable images was lack of participant cooperation.
Some participants are unable, or find it difficult, to sit
with their chin on the rest and forehead forward. It can
also be difficult to evert the upper eyelid and keep it
everted and still during the scan. This did not seem to be
related to the severity of the scarring as we were certainly
able to scan many individuals with advanced clinical
grades. Participants were excluded if they had
trachomatous trichiasis so tended not to have the very
severe scarring which can be seen in advanced trachoma.
We have previously reported that DFCs detected by
IVCM in the tarsal conjunctiva are independently associ-
ated with trachomatous scarring.19 This study showed
that DFCs present at the 24 month follow-up were also
associated with clinical scarring progression.19 Corneal
DFCs detected with IVCM are generally thought to be
dendritic cells, although this has not been conclusively
proven.24-27 When comparing IVCM findings with histo-
pathological conjunctival samples from patients with tra-
choma, there was a discordance between IVCM DFCs
and immunohistochemical dendritic cells.18 This may
have been due to the study methodology, or it is possible
that DFCs represent a different cell type. Whatever cell
type these structures represent, they appear to be associ-
ated with the scarring process in trachoma and it would
seem plausible that they are dendritic cells. Dendritic
cells are a key antigen presenting cell (APC), providing
an important role in immune tolerance and detection
and processing of antigens.28 Within the eye they are
found in corneal and conjunctival tissue. Repeated cycles
of immune-mediated inflammation from recurrent infec-
tion with C. trachomatis are central to trachoma
pathogenesis. As a key mediator of immune responses,
dendritic cells may play a role in pathogenesis of
trachomatous scarring, and may represent an opportu-
nity for disease modification through novel anti-fibrotic
agents.29-33
There was a similar association for DFCs present at
baseline and clinical scarring progression, but this was
less convincing after adjusting for other factors. In order
for this study to be feasible, this study formed part of a
series of studies on the pathogenesis of trachomatous
scarring.19 As a result, it was not specifically powered to
investigate IVCM predictors of clinical scarring progres-
sion, which is a limitation. As the number of individuals
with DFCs present at either baseline or follow-up were
relatively low this study may simply have not had suffi-
cient power to demonstrate a statistically significant
effect (a type II error).
IVCM is an expensive tool and not widely available,
particularly in lower and middle income countries. Fur-
thermore, it can be technically challenging to perform.
However, results from this study suggest that certain con-
focal parameters (connective tissue organization score
and presence of DFCs) provide proof of concept that
IVCM could be used as a tool for predicting clinical pro-
gression in other cicatricial conjunctival disorders that
are more common in developed countires. Similar
research into such disorders is therefore required.
We believe this to be the first study to investigate
the measurement of IVCM parameters in relation to
clinical scarring progression in trachoma. We have
demonstrated that increasing IVCM connective tissue
organization score at either baseline or follow-up, and
the presence of DFCs, are associated with clinical scar-
ring progression after adjusting for age. We did not,
however, find IVCM useful for determining whether
there had been clinical scarring progression in individ-
ual patients. IVCM has potential application to other
cicatricial conjunctival disorders, such as Stevens-
Johnson syndrome or ocular mucous membrane
pemphigoid, and further studies are required to explore




Jeremy J. Hoffman https://orcid.org/0000-0001-9454-
2131
REFERENCES
1. WHO Alliance for the Global Elimination of Trachoma by
2020. Progress report on elimination of trachoma, 2018. Wkly
Epidemiol Rec. 2018;93:369-380.
HOFFMAN ET AL. 7
2. Taylor HR, Burton MJ, Haddad D, West S, Wright H.
Trachoma. Lancet. 2014;384(9960):2142-2152.
3. Hu VH, Holland MJ, Burton MJ. Trachoma: protective and
pathogenic ocular immune responses to Chlamydia
trachomatis. PLoS Negl Trop Dis. 2013;7(2):e2020.
4. Stephens RS. The cellular paradigm of chlamydial pathogene-
sis. Trends Microbiol. 2003;11(1):44-51.
5. Ramadhani AM, Derrick T, Holland MJ, Burton MJ. Blinding
trachoma: systematic review of rates and risk factors for pro-
gressive disease. PLoS Negl Trop Dis. 2016;10(8):e0004859.
6. Jalbert I, Stapleton F, Papas E, Sweeney DF, Coroneo M. In
vivo confocal microscopy of the human cornea. Br J
Ophthalmol. 2003;87(2):225-236.
7. Guthoff RF, Zhivov A, Stachs O. In vivo confocal microscopy,
an inner vision of the cornea – a major review. Clin Experiment
Ophthalmol. 2009;37(1):100-117.
8. You JY, Botelho PJ. Corneal in vivo confocal microscopy: clini-
cal applications. R I Med J (2013). 2016;99(6):30-33.
9. Chiou AG-Y, Kaufman SC, Kaufman HE, Beuerman RW. Clin-
ical corneal confocal microscopy. Surv Ophthalmol. 2006;51(5):
482-500.
10. Mastropasqua L, Nubile M, Lanzini M, et al. Epithelial den-
dritic cell distribution in normal and inflamed human cornea:
in vivo confocal microscopy study. AJOPHT. 2006;142(5):
736-744.
11. Hu Y, Adan ES, Matsumoto Y, et al. Conjunctival in vivo con-
focal scanning laser microscopy in patients with atopic kerato-
conjunctivitis. Mol Vis. 2007;13:1379-1389.
12. Niederer RL, McGhee CNJ. Clinical in vivo confocal micros-
copy of the human cornea in health and disease. Prog Retin Eye
Res. 2010;29(1):30-58.
13. Vaddavalli PK, Garg P, Sharma S, Sangwan VS, Rao GN,
Thomas R. Role of confocal microscopy in the diagnosis of fungal
and acanthamoeba keratitis. Ophthalmology. 2011;118(1):29-35.
14. Chidambaram JD, Prajna NV, Larke NL, et al. Prospective
study of the diagnostic accuracy of the in vivo laser scanning
confocal microscope for severe microbial keratitis. Ophthalmol-
ogy. 2016;123(11):2285-2293.
15. Goh JWY, Harrison R, Hau S, Alexander CL, Tole DM,
Avadhanam VS. Comparison of in vivo confocal microscopy,
PCR and culture of corneal scrapes in the diagnosis of
acanthamoeba keratitis. Cornea. 2018;37(4):480-485.
16. Parmar DN, Awwad ST, Petroll WM, Bowman RW,
McCulley JP, Cavanagh HD. Tandem scanning confocal cor-
neal microscopy in the diagnosis of suspected acanthamoeba
keratitis. Ophthalmology. 2006;113(4):538-547.
17. Kanavi MR, Javadi M, Yazdani S, Mirdehghanm S. Sensitivity
and specificity of confocal scan in the diagnosis of infectious
keratitis. Cornea. 2007;26(7):782-786.
18. Hu VH, Holland MJ, Cree IA, et al. In vivo confocal micros-
copy and histopathology of the conjunctiva in trachomatous
scarring and normal tissue: a systematic comparison. Br J
Ophthalmol. 2013;97(10):1333-1337.
19. Hu VH, Weiss HA, Massae P, et al. In vivo confocal
microscopy in scarring trachoma. Ophthalmology. 2011;118
(11):2138-2146.
20. Hu VH, Massae P, Weiss HA, et al. In vivo confocal microscopy
of trachoma in relation to normal tarsal conjunctiva. Ophthal-
mology. 2011;118(4):747-754.
21. Hu VH, Macleod D, Massae P, et al. Non-chlamydial bacterial
infection and progression of conjunctival scarring in trachoma.
Invest Ophthalmol Vis Sci. 2018;59(6):2339-2344.
22. Hu VH, Massae P, Weiss HA, et al. Bacterial infection in
scarring trachoma. Invest Ophthalmol Vis Sci. 2011;52(5):2181-
2186.
23. Dawson CR, Jones BR, Tarizzo ML. Guide to Trachoma Con-
trol. Geneva: World Health Organization; 1981.
24. Mayer WJ, Mackert MJ, Kranebitter N, et al. Distribution of
antigen presenting cells in the human cornea: correlation of
in vivo confocal microscopy and immunohistochemistry in dif-
ferent pathologic entities. Curr Eye Res. 2012;37(11):1012-1018.
25. Liu M, Gao H, Wang T, Wang S, Li S, Shi W. An essential role
for dendritic cells in vernal keratoconjunctivitis: analysis by
laser scanning confocal microscopy. Clin Exp Allergy. 2014;44
(3):362-370.
26. Kheirkhah A, Rahimi Darabad R, Cruzat A, et al. Corneal epi-
thelial immune dendritic cell alterations in subtypes of dry eye
disease: a pilot in vivo confocal microscopic study. Invest
Ophthalmol Vis Sci. 2015;56(12):7179-7185.
27. Leonardi A, Lazzarini D, Bortolotti M, Piliego F, Midena E,
Fregona I. Corneal confocal microscopy in patients with vernal
keratoconjunctivitis. Ophthalmology. 2012;119(3):509-515.
28. Forrester JV, Xu H, Kuffová L, Dick AD, McMenamin PG.
Dendritic cell physiology and function in the eye. Immunol
Rev. 2010;234(1):282-304.
29. Holland MJ, Bailey RL, Conway DJ, et al. T helper type-1
(Th1)/Th2 profiles of peripheral blood mononuclear cells
(PBMC); responses to antigens of chlamydia trachomatis in
subjects with severe trachomatous scarring. Clin Exp Immunol.
1996;105(3):429-435.
30. Holland MJ, Bailey RL, Hayes LJ, Whittle HC, Mabey DC.
Conjunctival scarring in trachoma is associated with depressed
cell-mediated immune responses to chlamydial antigens.
J Infect Dis. 1993;168(6):1528-1531.
31. Mascellino MT, Boccia P, Oliva A. Immunopathogenesis in
chlamydia trachomatis infected women. ISRN Obstet Gynecol.
2011;2011(3):436936-436939.
32. Banchereau J, Briere F, Caux C, et al. Immunobiology of den-
dritic cells. Annu Rev Immunol. 2000;18(1):767-811.
33. Sato K, Fujita S. Dendritic cells: nature and classification.
Allergol Int. 2007;56(3):183-191.
How to cite this article: Hoffman JJ, Massae P,
Weiss HA, Makupa W, Burton MJ, Hu VH. In vivo
confocal microscopy and trachomatous
conjunctival scarring: Predictors for clinical
progression. Clin Experiment Ophthalmol. 2020;
1–8. https://doi.org/10.1111/ceo.13843
8 HOFFMAN ET AL.
